3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Advanced Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
palbociclib
2
Trastuzumab
2
Capecitabine
2
trastuzumab deruxtecan
1
tetrathiomolybdate
1
sacituzumab govitecan
1
pembrolizumab
1
niraparib
1
inavolisib
1
giredestrant
1
eribulin
1
avelumab
1
atezolizumab
1
abemaciclib
1
Zymosan
1
Radiotherapy
1
Letrozole
1
Immunotherapy
1
Hydroxychloroquine
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled